Related Experiment Video
Updated: Sep 19, 2025
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
10.3K
Faricimab Outcomes in Chorioretinal Disorders: Indian Real-World Analysis (FOCUS Study).
Vishal Agrawal1, Ayushi Gupta1, Virendra Agrawal2
1Department of Retina, Agrawal Hospital, Jaipur, India.
Clinical Ophthalmology (Auckland, N.Z.)
|June 18, 2025
Summary
Intravitreal faricimab significantly improved vision and reduced retinal swelling in Indian patients with diabetic macular edema, nAMD, and RVO. This dual-action therapy showed promising real-world safety and efficacy for these retinal conditions.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), and retinal vein occlusion (RVO) are leading causes of vision loss.
- Intravitreal therapies are crucial for managing these chorioretinal disorders.
- Faricimab, a novel dual-acting antibody, targets angiopoietin-2 and VEGF-A.
Purpose of the Study:
- To evaluate the real-world effectiveness and safety of intravitreal faricimab.
- To assess outcomes in Indian patients with DME, nAMD, and RVO-associated CME.
- To analyze changes in visual acuity and macular thickness following faricimab treatment.
Main Methods:
- Retrospective observational study of 49 patients (49 eyes) treated with intravitreal faricimab.
- Follow-up at four-week intervals for at least 24 weeks.
- Outcome measures included best-corrected visual acuity (BCVA), central macular thickness (CMT), and fluid resolution (IRF/SRF).
Main Results:
- Significant improvements in BCVA and reductions in CMT were observed across all patient groups (DME, nAMD, RVO).
- Faricimab led to substantial decreases in intraretinal (IRF) and subretinal fluid (SRF) in nAMD patients.
- No significant adverse events, including intraocular inflammation, were reported.
Conclusions:
- Intravitreal faricimab demonstrated significant visual and anatomical benefits in a real-world Indian population.
- The study supports faricimab's efficacy for DME, nAMD, and RVO, including off-label use for RVO-associated CME.
- These findings align with clinical trial data, highlighting faricimab's potential as a dual-action therapy for chorioretinal diseases.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
597
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
597
01:28Angle Closure Glaucoma: Treatment
718
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
718